Inflammatory bowel diseases ( IBD) are complex and multifactorial diseases that require a differentiated and evolving treatment approach. When monotherapies reach their limits, the need for combination strategies grows. The focus is on both conventional combination regimens and innovative applications of dual biological (targeted) therapies.
Partner
Autoren
- PD Dr. med. Pascal Juillerat
- Prof. Dr. med. Stephan Brand
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Peristomal skin health
Focus on preventive care options
- Mental Health with GLP-1 RAs
Benefits of Semaglutide and Liraglutide
- Bronchiolitis obliterans
Out of shape even without popcorn
- Case study
Guillain-Barré syndrome with a fulminant course
- Suspicion of neuroborreliosis?
Detection of borrelia-specific CSF parameters provides certainty
- The Brain and the Motivation to Eat
Why is it so hard to lose weight?
- Global Recommendation, Swissmedic Approval, and SL Limitation
WHO Guidelines on GLP-1 for Obesity
- Obesity in Children and Adolescents